Long lasting synthetic glucagon-like peptide {GLP-1}
View Patent ↗Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified peptides are administered to treat humans with diabetes and other related diseases.
1. The compound D-Ala 8 GLP-1 (7-36)-Lys 37 (ε-(AEEA)-MPA)-NH 2 .
2. A composition for treating diabetes or enhancing the expression of insulin in a patient, comprising a compound as claimed in claim 1 in association with a pharmaceutically acceptable carrier.
3. A conjugate comprising a compound as claimed in claim 1 covalently bonded to a blood protein.
4. A conjugate as claimed in claim 3 wherein the blood protein is serum albumin.
5. A composition for treating diabetes or enhancing the expression of insulin in a patient, comprising a conjugate as claimed in claim 3 in association with a pharmaceutically acceptable carrier.
6. A composition for treating diabetes or enhancing the expression of insulin in a patient, comprising a conjugate as claimed in claim 4 in association with a pharmaceutically acceptable carrier.
7. A composition comprising the compound of claim 1 .
8. A composition comprising the conjugate of claim 3 .
9. A composition comprising the conjugate of claim 4 .